The introduction of PET/MR with the use of PSMA as a radiotracer offers the potential to add a new biomarker to the well-established mnMRI. Different PSMA metrics such as SUV, metabolic tumor volume (MTV) and kinetic parameters can be correlated with lesion detection rate and Gleason score and help tailoring the precise treatment to patients.